Table 3.
Multivariable analyses of clinical factors associated with 30-day mortality from last radiation therapy treatment
| All patients (N = 636) |
Primary site* |
|||||
|---|---|---|---|---|---|---|
| Lung (n = 349) |
Not lung (n = 287) |
|||||
| Factor | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value |
| Age | 1.00 (0.98-1.03) | .75 | 1.01 (0.96-1.06) | .710 | 0.99 (0.96-1.03) | .937 |
| Karnofsky Performance Status | 0.95 (0.93-0.97) | <.001 | 0.96 (0.93-0.99) | .004 | 0.96 (0.93-0.99) | .012 |
| Brain metastases at initial diagnosis vs metachronous presentation | 0.45 (0.21-0.96) | .04 | 0.29 (0.11-0.75) | .01 | 1.23 (0.35-4.32) | .744 |
| Primary site, lung vs not lung | 1.31 (0.62-2.78) | .48 | - | - | - | - |
| Metastases, no. | .10 | .467 | .017 | |||
| 1-5 | Reference | Reference | Reference | |||
| 6-10 | 0.18 (0.02-1.43) | - | 0.51 (0.06-4.63) | |||
| 11-40 | 2.05 (0.61-6.83) | 3.43 (0.71-16.54) | 1.13 (0.13-10.03) | |||
| Innumerable | 2.17 (1.00-4.68) | 0.84 (0.25-2.77) | 5.41 (1.76-16.63) | |||
| Leptomeningeal disease | 1.13 (0.35-3.68) | .83 | 1.23 (0.11-13.34) | .863 | 0.80 (0.21-3.07) | .748 |
| Progressive intrathoracic metastases | 4.67 (2.06-10.60) | .002 | 7.72 (2.10-27.67) | .002 | 4.34 (1.41-13.39) | .011 |
| Progressive liver or adrenal metastases | 2.20 (1.16-4.16) | .02 | 3.03 (1.25-7.38) | .014 | 1.69 (0.63-4.55) | .297 |
| Any neurologic symptoms | 0.73 (0.35-1.52) | .40 | 0.87 (0.33-2.31) | .776 | 0.71 (0.21-2.36) | .576 |
| Place of radiation, inpatient vs outpatient | 4.51 (1.78-11.42) | .002 | 10.63 (3.02-37.43) | <.001 | 3.27 (0.81-13.26) | .098 |
| Outpatient palliative care utilization | 0.45 (0.20-1.00) | .05 | - | - | - | - |
Abbreviation: OR = odds ratio.
⁎
The model containing outpatient palliative care utilization within the lung subgroup does not converge.